EF-CBP1 Inhibitors
EF-CBP1 inhibitors are a class of chemical compounds that specifically target and modulate the activity of EF-CBP1, a protein that is part of the EF-hand calcium-binding protein family. EF-CBP1, like other proteins in this family, plays a crucial role in regulating intracellular calcium levels, which are essential for a wide range of cellular processes including signal transduction, muscle contraction, and the activation of various enzymes. The EF-hand motif, a characteristic feature of these proteins, is a helix-loop-helix structural domain that allows for the binding of calcium ions. When calcium binds to EF-CBP1, the protein undergoes conformational changes that enable it to interact with other proteins and molecules within the cell, thereby influencing various signaling pathways and cellular functions.
Inhibitors of EF-CBP1 work by disrupting the normal function of this protein, either by preventing calcium from binding to its EF-hand motifs or by altering its ability to interact with target proteins. These inhibitors may bind directly to the calcium-binding sites on EF-CBP1, effectively blocking the binding of calcium and preventing the subsequent conformational changes necessary for the protein's activity. Alternatively, inhibitors may induce structural changes in EF-CBP1 that impair its ability to engage with other proteins, thereby modulating the signaling pathways that depend on EF-CBP1 activity. By inhibiting EF-CBP1, these compounds serve as valuable tools for researchers aiming to understand the specific roles this protein plays in calcium signaling and how it contributes to the regulation of various cellular processes. The study of EF-CBP1 inhibitors can provide insights into the broader mechanisms of calcium-dependent signaling in cells, helping to elucidate the complex networks that govern cellular responses to changes in calcium levels and other intracellular signals.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, an HDAC inhibitor, could increase histone acetylation, leading to a more open chromatin structure and potentially a decrease in EF-CBP1 transcription. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
By inhibiting DNA methyltransferase, 5-Azacytidine could cause hypomethylation of the EF-CBP1 gene promoter, which may result in decreased expression of the EF-CBP1 gene. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
Mocetinostat may specifically target HDAC enzymes, leading to hyperacetylation of histones near the EF-CBP1 gene, potentially reducing its expression levels. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG 108 could prevent DNA methyltransferase from adding methyl groups to the EF-CBP1 gene, potentially lowering the transcriptional activity of the gene. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine might cause demethylation of the EF-CBP1 promoter region, which could lead to a reduced rate of EF-CBP1 gene transcription. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus could downregulate EF-CBP1 expression by inhibiting the mTOR signaling pathway, which is crucial for the initiation of protein translation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin may suppress EF-CBP1 protein synthesis by inhibiting mTOR, a key regulator of cell growth and protein translation processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib could disrupt the degradation of ubiquitinated proteins, potentially leading to altered cellular signaling and a decrease in EF-CBP1 expression. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone could bind to glucocorticoid receptors and alter the transcription of target genes, possibly leading to a downregulation of EF-CBP1 expression. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
Pladienolide B may disrupt the spliceosome, leading to aberrant splicing of pre-mRNAs, which could include the mRNA of EF-CBP1, resulting in decreased functional protein. | ||||||